Genclis SA is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented process that begins by analyzing differences between RNA and DNA sequences to identify translated proteins capable of causing the production of either Immunoglobulin E (“IgE”), the antibody responsible for most forms of allergies or Immunoglobulin G (“IgG”), the workhorse of immunity that accounts for most of vaccine efficacy. Genclis uses its proprietary patented platform technology to develop therapies that elicit self-produced antibodies that block disease-causing proteins irrespective of their endogenous or exogenous origin.
Science of TI
Transcription infidelity An Ubiquitous Biological process